WALTHAM, Mass- Thermo Fisher Scientific the world leader in serving science, has received three R&D 100 Awards for innovations that aid researchers’ and scientists’ work in a variety of life science applications, including proteomics, bioproduction and small-molecule analysis. Notably, the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) won gold in the Market Disruptor special recognition category as one of the most significant advancements in mass spectrometry in 15 years.
This first-of-its-kind instrument, also recognized in the Analytical/Test Category for the R&D 100 Awards, combines fast throughput, high sensitivity, and deep proteome coverage, enabling researchers to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. The Orbitrap Astral MS delivers up to two times deeper proteome coverage and four times the throughput of current mass spectrometers. Further demonstrating the instrument’s impact, over 40 peer-reviewed and preprint publications have been published on the Orbitrap Astral MS since launch in 2023. The instrument is accelerating precision medicine by helping researchers reveal disease signatures earlier and develop new interventions for everything from cardiovascular disease to cancer.
Also Read: Thermo Fisher Scientific Launches New CXCL10 Testing Service
Recognized in the Mechanical/Materials category, the Gibco™ CTS™ Detachable Dynabeads™ (CTS Detachable Dynabeads) platform offers the first active release mechanism of its kind for clinical trial and commercial manufacturing use. The active release mechanism of CTS Detachable Dynabeads utilizes a release buffer that enables users to actively release Dynabeads from a target cell at any time point within their manufacturing process, resulting in manufacturing cost savings while delivering high cell purity, yield and viability. These benefits help cell therapy developers get more life-changing treatments to patients faster, especially for those diagnosed with complex diseases such as blood cancers.
“At Thermo Fisher, our mission is to enable our customers to make the world healthier, cleaner, and safer by using our solutions and technologies to push the boundaries of science and make groundbreaking discoveries,” said Karen Nelson, chief scientific officer, Thermo Fisher Scientific.
These advances are part of Thermo Fisher’s $1.3 billion investment in R&D across the company’s businesses to deliver new technologies that are helping customers address some of the world’s greatest challenges.
Established in 1963, the R&D 100 Awards is the only science and technology awards competition that recognizes new commercial products, technologies and materials that are available for sale or license for their technological significance.
